Make pharmaceutical-related policy decisions using the best available clinical evidence.


The Drug Effectiveness Review Project (DERP)

is a collaborative of state Medicaid and public pharmacy programs. DERP produces concise, comparative, evidence-based reports that assist policymakers and other decision-makers grappling with difficult drug coverage decisions. Nationally recognized for its clinical objectivity and high-quality research, DERP focuses on specialty and other high-impact drugs— particularly those that have potential to change clinical practice. DERP reports evaluate efficacy, effectiveness, and safety of drugs to ultimately help improve patient safety and quality of care. Know you’re ready to join the DERP collaborative? Get in touch with the Center today. Not quite sure? Read on to learn more.


Benefits of Joining DERP

High quality

DERP delivers the best available clinical evidence on which to base policy decisions related to pharmaceuticals. DERP reports:

  • compare the effectiveness of drugs commonly used for the same conditions, highlight safety issues, and assist public pharmacy programs to enact policies that help increase the quality of patient care
  • include a comprehensive search of the global evidence, an objective appraisal of the quality of the studies found, and a thorough synthesis of high-quality evidence

Although the reports do not include cost data, policymakers are able to use the reports to make informed policy decisions that save money.

Independently governed

DERP is the only self-governed national forum available to public agencies. It uses a collaborative model and provides objective research on drug effectiveness to bring evidence to drug policy decisions. The research is conducted by investigators who have no financial or other conflicts of interest in the pharmaceuticals they study.

Improved Drug Safety

  • DERP reports are used to develop prior authorization and drug utilization management policies
  • Reports include up-to-date clinical evidence on adverse events and safety information of the drugs reviewed and have highlighted risks associated with the drugs studied before other sources ƒ
  • DERP reports are used to develop practice guidelines and provider education products to manage drugs with substantial off-label use


DERP participants have access to a unique forum to share ideas and collaboratively problem-solve policy issues, discuss evidence reviews, exchange ideas on programs and processes, and define the research agenda. This includes biannual conferences, monthly conference calls, weekly updates, and regular email exchanges.


The DERP Clearinghouse, which is only available to participating organizations, includes over 130 proprietary reports, covering 37 of the most commonly used drug classes. Translational tools available to participating organizations include summary documents for P&T Committees and clinicians.

Join Us

Is the Center the right resource for your needs and challenges?

Get in touch with us today